Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 172

1.

Efficacy and safety of rituximab in type II mixed cryoglobulinemia.

Zaja F, De Vita S, Mazzaro C, Sacco S, Damiani D, De Marchi G, Michelutti A, Baccarani M, Fanin R, Ferraccioli G.

Blood. 2003 May 15;101(10):3827-34. Epub 2003 Jan 30.

2.

Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids.

Quartuccio L, Soardo G, Romano G, Zaja F, Scott CA, De Marchi G, Fabris M, Ferraccioli G, De Vita S.

Rheumatology (Oxford). 2006 Jul;45(7):842-6. Epub 2006 Jan 17.

PMID:
16418196
3.
4.

Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis.

Roccatello D, Baldovino S, Rossi D, Mansouri M, Naretto C, Gennaro M, Cavallo R, Alpa M, Costanzo P, Giachino O, Mazzucco G, Sena LM.

Nephrol Dial Transplant. 2004 Dec;19(12):3054-61. Epub 2004 Oct 19.

PMID:
15494358
5.

Rituximab in mixed cryoglobulinemia: increased experience and perspectives.

De Vita S, Quartuccio L, Fabris M.

Dig Liver Dis. 2007 Sep;39 Suppl 1:S122-8.

PMID:
17936213
6.

Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand?

Cacoub P, Delluc A, Saadoun D, Landau DA, Sene D.

Ann Rheum Dis. 2008 Mar;67(3):283-7. Epub 2007 Jul 20. Review.

7.

Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature.

Ferri C, Cacoub P, Mazzaro C, Roccatello D, Scaini P, Sebastiani M, Tavoni A, Zignego AL, De Vita S.

Autoimmun Rev. 2011 Nov;11(1):48-55. doi: 10.1016/j.autrev.2011.07.005. Epub 2011 Jul 24. Review.

8.

Efficacy of low-dose rituximab for mixed cryoglobulinemia.

Visentini M, Granata M, Veneziano ML, Borghese F, Carlesimo M, Pimpinelli F, Fiorilli M, Casato M.

Clin Immunol. 2007 Oct;125(1):30-3. Epub 2007 Aug 9.

PMID:
17692572
9.

Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease.

Petrarca A, Rigacci L, Caini P, Colagrande S, Romagnoli P, Vizzutti F, Arena U, Giannini C, Monti M, Montalto P, Matucci-Cerinic M, Bosi A, Laffi G, Zignego AL.

Blood. 2010 Jul 22;116(3):335-42. doi: 10.1182/blood-2009-11-253948. Epub 2010 Mar 22.

10.

Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20.

Sansonno D, De Re V, Lauletta G, Tucci FA, Boiocchi M, Dammacco F.

Blood. 2003 May 15;101(10):3818-26. Epub 2002 Dec 27.

11.

Improvement in liver cirrhosis after treatment of HCV-related mixed cryoglobulinemia with rituximab.

Petrarca A, Rigacci L, Monti M, Giannini C, Bernardi F, Caini P, Colagrande S, Bosi A, Laffi G, Zignego AL.

Dig Liver Dis. 2007 Sep;39 Suppl 1:S129-33.

PMID:
17936214
12.

Rituximab may form a complex with IgMkappa mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis.

Sène D, Ghillani-Dalbin P, Amoura Z, Musset L, Cacoub P.

Arthritis Rheum. 2009 Dec;60(12):3848-55. doi: 10.1002/art.25000.

13.

Clinical and morphologic spectrum of renal involvement in patients with mixed cryoglobulinemia without evidence of hepatitis C virus infection.

Matignon M, Cacoub P, Colombat M, Saadoun D, Brocheriou I, Mougenot B, Roudot-Thoraval F, Vanhille P, Moranne O, Hachulla E, Hatron PY, Fermand JP, Fakhouri F, Ronco P, Plaisier E, Grimbert P.

Medicine (Baltimore). 2009 Nov;88(6):341-8. doi: 10.1097/MD.0b013e3181c1750f.

14.

Restoration of peripheral immune homeostasis after rituximab in mixed cryoglobulinemia vasculitis.

Saadoun D, Rosenzwajg M, Landau D, Piette JC, Klatzmann D, Cacoub P.

Blood. 2008 Jun 1;111(11):5334-41. doi: 10.1182/blood-2007-11-122713. Epub 2008 Feb 21.

15.

Rituximab therapy for de novo mixed cryoglobulinemia in renal transplant patients.

Basse G, Ribes D, Kamar N, Mehrenberger M, Esposito L, Guitard J, Lavayssière L, Oksman F, Durand D, Rostaing L.

Transplantation. 2005 Dec 15;80(11):1560-4. Erratum in: Transplantation. 2006 Sep 15;82(5):715. Dur, Dominique [corrected to Durand, Dominique].

PMID:
16371926
16.

Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) for Sjögren's syndrome-associated B-cell aggressive non-Hodgkin's lymphomas.

Voulgarelis M, Giannouli S, Anagnostou D, Tzioufas AG.

Rheumatology (Oxford). 2004 Aug;43(8):1050-3. Epub 2004 Jun 8.

PMID:
15187246
17.

A phase II, single-arm multicenter study of low-dose rituximab for refractory mixed cryoglobulinemia secondary to hepatitis C virus infection.

Visentini M, Ludovisi S, Petrarca A, Pulvirenti F, Zaramella M, Monti M, Conti V, Ranieri J, Colantuono S, Fognani E, Piluso A, Tinelli C, Zignego AL, Mondelli MU, Fiorilli M, Casato M.

Autoimmun Rev. 2011 Sep;10(11):714-9. doi: 10.1016/j.autrev.2011.04.033. Epub 2011 May 5.

PMID:
21570494
18.

Rituximab for the treatment of glomerulonephritis in hepatitis C associated cryoglobulinaemia.

Korte MR, van Heerde MJ, de Man RA, Betjes MH.

Neth J Med. 2008 Jan;66(1):27-30.

PMID:
18219065
19.

Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: data from the French Autoimmunity and Rituximab registry.

Terrier B, Launay D, Kaplanski G, Hot A, Larroche C, Cathébras P, Combe B, de Jaureguiberry JP, Meyer O, Schaeverbeke T, Somogyi A, Tricot L, Zénone T, Ravaud P, Gottenberg JE, Mariette X, Cacoub P.

Arthritis Care Res (Hoboken). 2010 Dec;62(12):1787-95. doi: 10.1002/acr.20318.

20.

Rituximab therapy for mixed cryoglobulinemia in seven renal transplant patients.

Basse G, Ribes D, Kamar N, Mehrenberger M, Sallusto F, Esposito L, Guitard J, Lavayssière L, Oksman F, Durand D, Rostaing L.

Transplant Proc. 2006 Sep;38(7):2308-10.

PMID:
16980074

Supplemental Content

Support Center